BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) was the target of a large increase in short interest in October. As of October 31st, there was short interest totalling 86,300 shares, an increase of 72.6% from the October 15th total of 50,000 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average daily volume of 831,300 shares, the days-to-cover ratio is presently 0.1 days.

BioCardia Stock Performance

Shares of BCDA stock traded down $0.17 during mid-day trading on Friday, hitting $1.85. The company’s stock had a trading volume of 76,961 shares, compared to its average volume of 297,346. BioCardia has a 52 week low of $1.84 and a 52 week high of $14.40. The company’s fifty day simple moving average is $2.59 and its 200-day simple moving average is $3.36. The company has a market cap of $3.93 million, a PE ratio of -0.48 and a beta of 1.28.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.78). On average, equities analysts anticipate that BioCardia will post -5.06 earnings per share for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $25.00 price target on shares of BioCardia in a report on Thursday.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.